3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer

ConditionsBrain and Central Nervous System Tumors Chronic Myeloproliferative Disorders Leukemia Lymphoma Lymphoproliferative Disorder Multiple Myeloma and Plasma Cell Neoplasm Myelodysplastic Syndromes Myelodysplastic/Myeloproliferative Neoplasms Unspecified Adult Solid Tumor, Protocol Specific

Trial statusRecruiting

Trial phaseNot listed

Trial typeInterventional

Biological sexAll

Age18-120

SponsorBarbara Ann Karmanos Cancer Institute

About this trial

RATIONALE: Diagnostic procedures, such as 3'-deoxy-3'-\[18F\] fluorothymidine (FLT) PET imaging, may help find and diagnose cancer. It may also help doctors predict a patient's response to treatment and help plan the best treatment.

PURPOSE: This phase I trial is studying FLT PET imaging in patients with cancer.

Eligibility criteria

Qualifiers

Histologically confirmed solid tumor or hematologic malignancy

Awaiting biopsy or surgery for cancer evaluation of a mass detected on exam or standard imaging

Able to lie still in the PET scanner

Girth and weight must be suitable to enter the gantry

Disqualifiers

None

Trial design

Treatments tested in this trial

3'-deoxy-3'-[18F]fluorothymidine

Treatment groups

Not listed Participants

are divided into 1 treatment group

Sponsors and collaborators

Barbara Ann Karmanos Cancer Institute

Lead sponsor

National Cancer Institute (NCI)

Collaborator

Source ClinicalTrials.gov